Last updated on December 2018

A prostate cancer study that will evaluate safety and efficacy of niraparib in combination with other anti-cancer agents

Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions: Bone Neoplasm | Urologic Cancer | Metastatic Cancer | Prostate Cancer | Adenocarcinoma
  • Age: Between 18 - 100 Years
  • Gender: Male


Inclusion Criteria:

  • Participants willing to undergo all protocol-specified biopsies Diagnosis of prostate adenocarcinoma as confirmed by the investigator
  • Must have determination of biomarker (BM) status (either BM positive [+] or BM negative [-]) by the sponsor's blood based assay
  • Participants must have measurable disease as defined by response evaluation criteria in solid tumors (RECIST) 1.1 (soft tissue lesion of greater than or equal to (>=) 10 millimeter (mm) in the long axis or extrapelvic lymph node of >=15 mm in the short axis)
  • Must have previously received at least 1, but no more than 2, lines of novel androgen receptor (AR)-targeted therapy (for example, abiraterone acetate with prednisone, enzalutamide, apalutamide) for prostate cancer.
  • Participants must have had at least 4 weeks of AR-targeted therapy


Exclusion Criteria:

  • Prior treatment with a poly (adenosine diphosphate [ADP]-ribose) polymerase (PARP) inhibitor
  • History or current diagnosis of myelodysplastic syndrome (MDS)/acute myeloid leukemia (AML)
  • Active malignancy (exceptions: adequately treated basal cell or squamous cell skin cancer, superficial bladder cancer, or any other cancer in situ currently remission) less than or equal to (<=) 2 years prior to enrollment
  • Active infection requiring systemic therapy Allergies, hypersensitivity, or intolerance to niraparib or the corresponding excipients

Recruitment Status: Open

Brief Description Eligibility Contact Research Team

Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.